Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

8,440 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Cabozantinib for Advanced Hepatocellular Carcinoma in the Latest Real-World Practice: A Multicenter Retrospective Analysis.
Kanzaki H, Ogasawara S, Okubo T, Itokawa N, Yoshino R, Fujimoto K, Kogure T, Yumita S, Ishino T, Ogawa K, Iwanaga T, Nakagawa M, Fujiwara K, Kojima R, Koroki K, Inoue M, Kobayashi K, Kanogawa N, Kiyono S, Nakamura M, Kondo T, Nakagawa R, Nakamoto S, Muroyama R, Itobayashi E, Atsukawa M, Kato J, Kato N. Kanzaki H, et al. Among authors: inoue m. Drugs Real World Outcomes. 2023 Dec;10(4):513-520. doi: 10.1007/s40801-023-00379-x. Epub 2023 Jul 19. Drugs Real World Outcomes. 2023. PMID: 37466822 Free PMC article.
Successful Treatment of Hepatocellular Carcinoma Complicated by Fanconi Anemia.
Takahashi K, Suzuki E, Yokoyama M, Inoue M, Wakamatsu T, Saito T, Kusakabe Y, Ogasawara S, Ooka Y, Tawada A, Nagao Y, Nakaseko C, Chiba T. Takahashi K, et al. Among authors: inoue m. Case Rep Gastroenterol. 2017 Jan 27;11(1):29-35. doi: 10.1159/000454710. eCollection 2017 Jan-Apr. Case Rep Gastroenterol. 2017. PMID: 28203135 Free PMC article.
Characteristics of patients with sorafenib-treated advanced hepatocellular carcinoma eligible for second-line treatment.
Ogasawara S, Chiba T, Ooka Y, Suzuki E, Maeda T, Yokoyama M, Wakamatsu T, Inoue M, Saito T, Kobayashi K, Kiyono S, Nakamura M, Nakamoto S, Yasui S, Tawada A, Arai M, Kanda T, Maruyama H, Yokosuka O, Kato N. Ogasawara S, et al. Among authors: inoue m. Invest New Drugs. 2018 Apr;36(2):332-339. doi: 10.1007/s10637-017-0507-3. Epub 2017 Sep 11. Invest New Drugs. 2018. PMID: 28891038
Henoch-Schönlein Purpura Complicated by Hepatocellular Carcinoma.
Akizue N, Suzuki E, Yokoyama M, Inoue M, Wakamatsu T, Saito T, Kusakabe Y, Ogasawara S, Ooka Y, Tawada A, Maru Y, Matsue H, Chiba T. Akizue N, et al. Among authors: inoue m. Intern Med. 2017 Nov 15;56(22):3041-3045. doi: 10.2169/internalmedicine.8885-17. Epub 2017 Sep 25. Intern Med. 2017. PMID: 28943572 Free PMC article.
Transarterial chemoembolization as a substitute to radiofrequency ablation for treating Barcelona Clinic Liver Cancer stage 0/A hepatocellular carcinoma.
Ishikawa K, Chiba T, Ooka Y, Suzuki E, Ogasawara S, Maeda T, Yokoyama M, Inoue M, Wakamatsu T, Kusakabe Y, Saito T, Tawada A, Arai M, Kanda T, Maruyama H, Imazeki F, Kato N. Ishikawa K, et al. Among authors: inoue m. Oncotarget. 2018 Apr 20;9(30):21560-21568. doi: 10.18632/oncotarget.25108. eCollection 2018 Apr 20. Oncotarget. 2018. PMID: 29765560 Free PMC article.
Sequential therapy with sorafenib and regorafenib for advanced hepatocellular carcinoma: a multicenter retrospective study in Japan.
Ogasawara S, Ooka Y, Itokawa N, Inoue M, Okabe S, Seki A, Haga Y, Obu M, Atsukawa M, Itobayashi E, Mizumoto H, Sugiura N, Azemoto R, Kanayama K, Kanzaki H, Maruta S, Maeda T, Kusakabe Y, Yokoyama M, Kobayashi K, Kiyono S, Nakamura M, Saito T, Suzuki E, Nakamoto S, Yasui S, Tawada A, Chiba T, Arai M, Kanda T, Maruyama H, Kato N. Ogasawara S, et al. Among authors: inoue m. Invest New Drugs. 2020 Feb;38(1):172-180. doi: 10.1007/s10637-019-00801-8. Epub 2019 Jun 6. Invest New Drugs. 2020. PMID: 31172442
8,440 results